POST-COVID CONDITION - PULMONARY OR SYSTEMIC, REVERSIBLE OR IRREVERSIBLE?
Abstract
Covid patients are being discharged from hospitals without assessment of the degree of their recovery. Large number of patients fully recovers after covid. However, over 30% of patients have prolonged symptoms, independent from the severity of their clinical picture. There is no correlation between severe acute COVID and severe post-COVID syndrome. According to the NICE 2020 recommendations, the term long covid includes symptomatic COVID-19 (period 4-12 weeks after acute disease) and post- COVID-19 syndrome. According to the WHO post-COVID-19 syndrome is a condition in persons with history of probable or confirmed COVID infection, usually 3 months from the onset of COVID-19, with symptoms lasting at least 2 months, that cannot be explained by an alternative diagnosis. Intolerance to physical exertion, experiencing breathing difficulty and neuropsychiatric disorders are the most common and longest lasting difficulties. Most common respiratory post-COVID manifestation is persistent dyspnea, while persistent pulmonary fibrosis was extremely rare. In almost half of patients who have had severe COVID pneumonias, there were no absolute correlation between pulmonary function disorders and thoracic CT images, and disorders kept persisting after complete radiographic regression. Dominant manifestation of these disorders is reduced lung diffusion capacity for CO (TLCOc, KCOc), while spirometry values are mostly normal. Pulmonary thromboembolism, myocarditis, anxiety-depressive disorder, forgetfulness and hair loss are some of the serious post-COVID complications. Significant number of patients need physical rehabilitation.
References
1. Laban M. Da li postkovid zaista postoji? U: Stjepanović M, Popević S, Dimić-Janjić Sanja, urednici. Odabrana poglavlja iz pulmologije. Beograd: Medicinski fakultet u Beogradu; 2023.
2. Overview /COVID -19 rapid guideline: managing of long- term effects of COVID-19/ Guidance NICE. National Institute for Health and Care Excellence. 18 December 2020. Retrieved 18 December 2020..
3. Post COVID Conditions (e.g. LongCOVID). IDSA, last reviewed Oct 6, 2021.
4. Nasserie T, et al. Assessment of the Frequency and variety of persistent symptoms among patients with COVID 19: A systematic review. JAMA Netw Open.2021.
5. Fernandez-de-las Penas C, et al. Long-term post - COVID symptoms and associated risk factors in previously hospitalized patients: A multicenter study. J Infect 2021 Aug; 83 (2): 237- 279.
6. Liang L, et al. Three- month Follow-up Study of Survivors of Corona Disease 2019 after Discharge. J Korean Med Sci. 2020.
7. Chaolin Huang, Lixue Huang, Yeming Wang, Xia Li, Lili Ren, Xiaoying Gu, Liang Kang, Li Guo, Min Liu, Xing Zhou, Jianfeng Luo, Zhenghui Huang, Shengjin Tu, Yue Zhao, Li Chen, Decui Xu, Yanping Li, Caihong Li, Lu Peng, Yong Li, Wuxiang Xie, Dan Cui, Lianhan Shang, Guohui Fan, Jiuyang Xu, Geng Wang, Ying Wang, Jingchuan Zhong, Chen Wang Jianwei Wang, Dingyu Zhang, Bin Cao. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397: 220-32.
8. Maltezou H, Pavli A, Tsakris A, Post-COVID Syndrome: An Insight on Its Pathogenesis. Vaccines (Basel). 2021 May 12;9 (5):497.
9. Mazza MG, De Lorenzo R, Conte C, Polleti S, Benedetta V, Bolettini I, Melloni E, Furlan R, Ciceri F, Querini P, Benedetti F. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behal Immun 2020 Oct; 89: 594-600.
10. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJH. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. The Lancet, Vol 8, Issue 5; P416-427; May 01, 2021.
11. AD Desai, M Lavelle, BC Boursigout, EY Wan. Long-term complications of COVID-19. J Physiol Cell Physiol. 2022 Jan 1; 322(1): C1-C11.
12. Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, Heightman M, Hillman TE, Jacob J, Jarvis HC, Lipman MCI, Naidu SB, Nair A, Porter JC, Tomlinson GS, Hurst JR; ARC Study Group. Long -COVID: a cross -sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax 76: 396–398, 2021.
13. Long Term Effects of COVID 19. Centers for Disease Control and Prevention. Retrieved 27 November 2020.
14. Jovanović D. COVID 19 - odabrani aspekti, Beograd, Prof. dr Dragana Jovanović, 2021.
15. Ramacciotti E, Agati L, Calderaro D, at al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. The Lancet, Vol 399, Issue 10319; Jan01;2021, 50-59
16. E. Ganesanne. Pneumomediastinum in COVID-19 disease: Clinical review with emphasis on emergency management. J Am Coll Emerg Physicians Open. 2023 Apr; 4 (2):e12935.
17. Zhonghua Jie He He Hu Xi Za Zhi. Recommendations for respiratory rehabilitation of COVID -19 in adult. 202; 43(0): E029.
18. Zečević M, Kotur N, Ristivojević B, Gašić V, Škodrić -Trifunović V, Stjepanović M, Stevanović G, Lavadinović L, Zukić B, Pavlović S, Stanković B. Genome-Wide Association Study of COVID-19 Outcomes Reveals Novel Host Genetic Risk Loci in the Serbian Population. Front Genet. 2022 Jul 14;13:911010.
